throbber
1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`
`
`FISHER & PAYKEL HEALTHCARE
`CORPORATION LIMITED, a New Zealand
`Corporation, FISHER & PAYKEL
`HEALTHCARE LIMITED, a New Zealand
`Corporation, FISHER & PAYKEL
`HEALTHCARE INC., a California
`Corporation, FISHER & PAYKEL
`HOLDINGS INC., a California Corporation,
`and FISHER & PAYKEL HEALTHCARE
`DISTRIBUTION INC., a California
`Corporation
`
`
`
`Defendants.
`
`
`
`
`
`
`
`
`
`CASE NO._______
`
`Roger A. Denning, SBN 228998, denning@fr.com
`Todd Miller, SBN 163200, miller@fr.com
`Frank Albert, SBN 247741, albert@fr.com
`Fish & Richardson P.C.
`12390 El Camino Real
`San Diego, CA 92130
`Phone: 858-678-5070 / Fax: 858-678-5099
`
`Frank E. Scherkenbach, SBN 142549, scherkenbach@fr.com
`Fish & Richardson P.C.
`One Marina Park Dr.
`Boston, MA 02210
`Phone: 617-542-5070 / Fax: 617-542-8906
`
`Christina Brown Marshall SBN 280552, brown-marshall@fr.com
`Fish & Richardson P.C.
`1180 Peachtree Street, 21st Floor
`Atlanta, GA 30309
`Phone: 404-724-5005 / Fax: 404-892-5002
`
`Attorneys for Plaintiffs
`
`IN THE UNITED STATES DISTRICT COURT
`
`FOR THE SOUTHERN DISTRICT OF CALIFORNIA
`
`RESMED INC., a Delaware Corporation,
`CASE NO:
`
`RESMED CORP, a Minnesota Corporation,
`COMPLAINT FOR PATENT
`and RESMED LTD, an Australian
`INFRINGEMENT
`Corporation,
`
`JURY TRIAL DEMANDED
`
`
`
`Plaintiffs,
`
`
`v.
`
`'16
`
`CV2072
`
`MDD
`
`JAH
`
`1
`
`RMD 1046
`
`

`
`
`
`Plaintiff ResMed Inc, Plaintff ResMed Corp., and Plaintiff ResMed Ltd
`hereby complains of Defendant Fisher & Paykel Healthcare Corporation Limited,
`Defendant Fisher & Paykel Healthcare Limited, Defendant Fisher & Paykel
`Healthcare Inc., Defendant Fisher & Paykel Holdings Inc., and Fisher & Paykel
`Healthcare Distribution Inc. and alleges as follows:
`PARTIES
`1.
`Plaintiff ResMed Inc. is a corporation organized under the laws of the
`state of Delaware with its principal place of business in this district in San Diego,
`California.
`2.
`Plaintiff ResMed Corp is a corporation organized under the laws of the
`state of Minnesota with its principal place of business in this district in San Diego,
`California.
`3.
`Plaintiff ResMed Ltd is a corporation organized under the laws of
`Australia, having its principal place of business in Bella Vista, New South Wales,
`Australia.
`4.
`ResMed Corp and ResMed Ltd are, respectively, direct and indirect
`subsidiaries of ResMed Inc.
`5.
`As used herein, the term “Plaintiffs” or “ResMed” means individually
`and/or collectively ResMed Inc., ResMed Corp, and ResMed Ltd.
`6.
`On information and belief, Defendant Fisher & Paykel Healthcare
`Corporation Limited (“F&P Healthcare Corp. Ltd”) is a corporation organized under
`the laws of the country of New Zealand and is the overall parent company of Fisher
`& Paykel Healthcare entities.
`7.
`On information and belief, F&P Healthcare Corp. Ltd has its principal
`place of business at 15 Maurice Paykel Place, East Tamaki, Auckland 2013, New
`Zealand.
`
`
`
`
`
`
`
`1
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`2
`
`

`
`
`
`8.
`On information and belief, Defendant Fisher & Paykel Healthcare
`Limited (“F&P Healthcare Ltd”) is a New Zealand subsidiary of F&P Healthcare
`Corp. Ltd.
`9.
`On information and belief, F&P Healthcare Ltd is a corporation
`organized under the laws of the country of New Zealand.
`10. On information and belief, F&P Healthcare Ltd has its principal place
`of business at 15 Maurice Paykel Place, East Tamaki, Auckland 2013, New Zealand.
`11. On information and belief, Defendant Fisher & Paykel Holdings Inc.
`(“F&P Holdings Inc.”) is a U.S. subsidiary of F&P Healthcare Corp. Ltd.
`12. On information and belief, F&P Holdings Inc is a corporation
`organized under the laws of the state of California.
`13. On information and belief, F&P Holdings Inc. is a corporation with its
`principal place of business at 15365 Barranca Parkway, Irvine, CA 92618.
`14. On information and belief, Defendant Fisher & Paykel Healthcare Inc
`(“F&P Healthcare Inc.”) is a U.S. sales entity and subsidiary of F&P Holdings Inc.
`15. On information and belief, F&P Healthcare Inc. is a corporation
`organized under the laws of the state of California.
`16. On information and belief, F&P Healthcare Inc. is a corporation with
`its principal place of business at 15365 Barranca Parkway, Irvine, CA 92618.
`17. On information and belief, Fisher & Paykel Healthcare Distribution
`Inc. (“F&P Healthcare Dist.”) is a U.S. distribution entity and subsidiary of F&P
`Holdings Inc.
`18. On information and belief, F&P Healthcare Dist. is a corporation
`organized under the laws of the state of California.
`19. On information and belief, F&P Healthcare Dist. is a corporation with
`its principal place of business at 15365 Barranca Parkway, Irvine, CA 92618.
`
`
`
`
`
`
`
`2
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`3
`
`

`
`
`
`
`
`
`
`20. As used herein, the term “Defendants” or “F&P” means individually
`and/or collectively F&P Healthcare Corp. Ltd., F&P Healthcare Ltd., F&P Holdings
`Inc., F&P Healthcare Inc., and F&P Healthcare Dist.
`JURISDICTION AND VENUE
`21. This Court has subject matter jurisdiction over the claims pleaded
`herein under 28 U.S.C. §§ 1331 and 1338(a) because the actions below concern a
`federal question arising under the patent laws of the United States, including 35
`U.S.C. § 271.
`22. Venue is proper in this judicial district under 28 U.S.C. §§ 1391(b), (c)
`and 1400(b) because, among other reasons, F&P is subject to personal jurisdiction in
`this judicial district and has committed acts of infringement in this judicial district or
`will imminently commit acts of infringement in this judicial district.
`23. Upon information and belief, F&P has placed infringing products
`and/or will place infringing products into the stream of commerce by shipping those
`products into this judicial district and/or by knowing that such products would be
`shipped into this judicial district.
`24. F&P’s established distribution network distributes sleep-disordered
`breathing treatment systems and products directly to customers located in this
`district.
`25. For those products soon to be released in the United States, F&P’s
`established distribution network would distribute the sleep-disordered breathing
`treatment systems and directly to customers located in this district.
`26. For example, upon information and belief, F&P is a manufacturer and
`distributor of durable medical equipment, including systems and components thereof
`for the treatment of sleep-disordered breathing, such as obstructive sleep apnea.
`27. On information and belief, F&P develops, manufactures, and markets
`sleep-disordered breathing treatment systems and components thereof that infringe
`one or more claims of the Patents-in-Suit, as defined below.
`
`
`3
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`4
`
`

`
`
`
`28. On information and belief, F&P’s sleep-disordered breathing treatment
`systems and components thereof are manufactured, assembled, packaged, and/or
`tested outside of the United States.
`29.
` On information and belief, F&P then imports the accused sleep-
`disordered breathing treatment systems and components thereof into the United
`States, sells them for importation, or sells them in the United States after
`importation.
`30. Upon information and belief, F&P distributes the products nationally,
`including in this district.
`31. By importing into the United States, shipping into, selling, offering to
`sell, and/or using products that infringe the patents-in-suit in this district, or by
`inducing or causing those acts to occur, F&P has transacted and continues to
`transact business and perform work and services in this district, has supplied and
`continues to supply services and things in this district, has caused and continues to
`cause injury and damages in this district by acts and omissions in this district, and
`has caused and continues to cause injury and damages in this district by acts or
`omissions outside of this district while deriving substantial revenue from services or
`things used or consumed within this district, and will continue to do so unless
`enjoined by this Court.
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`
`
`
`
`THE PATENTS
`32. ResMed Ltd is the owner by assignment of all right, title, and interest
`in and to United States Patent No. 8,944,061 patent entitled “Cushion To Frame
`Assembly Mechanism,” (hereinafter “the ’061 patent”), which was duly and legally
`issued on February 3, 2015.
`33. The ’061 patent is valid, enforceable, and currently in full force and
`effect. A copy of the ’061 patent is attached as Exhibit A.
`34. ResMed Inc. is the exclusive licensee of the ’061 patent and has
`exclusively sublicensed the patent to ResMed Corp., the U.S. sales subsidiary.
`
`
`4
`
`CASE NO._______
`
`5
`
`

`
`
`
`35. ResMed Ltd. is the owner by assignment of all right, title, and interest
`in and to United States Patent No. 8,950,404 entitled “Headgear For Masks,”
`(hereinafter “the ’404 patent”), which was duly and legally issued on February 10,
`2015.
`36. The ’404 patent is valid, enforceable, and currently in full force and
`effect. A copy of the ’404 patent is attached as Exhibit B.
`37. ResMed Inc. is the exclusive licensee of the ’404 patent and has
`exclusively sublicensed the patent to ResMed Corp., the U.S. sales subsidiary.
`38. ResMed Ltd. is the owner by assignment of all right, title, and interest
`in and to United States Patent No. 9,027,556 entitled “Mask System,” (hereinafter
`“the ’556 patent”), which was duly and legally issued on May 12, 2015.
`39. The ’556 patent is valid, enforceable, and currently in full force and
`effect. A copy of the ’556 patent is attached as Exhibit C.
`40. ResMed Inc. is the exclusive licensee of the ’556 patent and has
`exclusively sublicensed the patent to ResMed Corp, the U.S. sales subsidiary.
`41. ResMed Ltd is the owner by assignment of all right, title, and interest
`in and to United States Patent No. 9,381,316 entitled “Interchangeable Mask
`Assembly,” (hereinafter “the ’316 patent”), which was duly and legally issued on
`July 5, 2016.
`42. The ’316 patent is valid, enforceable, and currently in full force and
`effect. A copy of the ’316 patent is attached as Exhibit D.
`43. ResMed Inc. is the exclusive licensee of the ’316 patent and has
`exclusively sublicensed the patent to ResMed Corp, the U.S. sales subsidiary.
`44. As used herein, the term “Patents-in-Suit” means individually and/or
`collectively the ’061 patent, the ’404 patent, the ’556 patent, and the ’316 patent.
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`
`
`
`
`
`
`5
`
`CASE NO._______
`
`6
`
`

`
`
`
`
`
`
`
`BACKGROUND
`45. ResMed is a leading developer, manufacturer and distributor of medical
`equipment for treating, diagnosing, and managing sleep-disordered breathing and
`other respiratory disorders.
`46. The company is dedicated to developing innovative products to
`improve the lives of those who suffer from these conditions and to increasing
`awareness among patients and healthcare professionals of the potentially serious
`health consequences of untreated sleep-disordered breathing (sometimes referred to
`as “SDB”).
`47. Since it was founded in 1989, ResMed has focused on developing and
`commercializing systems for the treatment of obstructive sleep apnea (“OSA”), a
`major subset of SDB.
`48. ResMed’s development of innovative therapies for the treatment of
`OSA has resulted in over 4,000 patents granted or pending worldwide, and its
`product line incorporates technology that is a highly effective and proven way to
`treat OSA.
`49. ResMed has invested hundreds of millions of dollars in research and
`development.
`50.
`It has been estimated that SDB in general, and OSA in particular,
`affects approximately 20% of the adult population, making it as widespread as
`diabetes or asthma.
`51. However, awareness of OSA is relatively low; one study in 2002
`concluded that about 90% of people with OSA remain undiagnosed and untreated.
`52. Therefore, ResMed has made substantial investments directed to
`increasing education and awareness of the health consequences of untreated SDB
`among both the general public and physicians.
`53. ResMed’s portfolio of SDB products includes flow generators,
`humidifiers, diagnostic products, mask systems, headgear and other accessories,
`
`
`6
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`7
`
`

`
`
`
`including, for example, certain sleep-disordered breathing treatment masks,
`including the Quattro Air, Quattro Air for Her, Quattro FX, Quattro FX for Her,
`AirFit N10, AirFit N10 for Her, AirFit F10, AirFit F10 for Her, Mirage FX, and
`Mirage FX for Her.
`54. ResMed marks its patents on some products and marks all of its
`products on its website at: www.resmed.com/ip.
`55. On information and belief, F&P, on its own and/or through its
`subsidiaries, is in the business of manufacturing, packaging, importing, selling,
`offering to sell, and/or distributing a variety of sleep-disordered breathing treatment
`systems and components thereof, including, but not limited to, F&P’s Eson product
`line, F&P’s Eson 2 product line, and F&P’s Simplus product line (collectively,
`“Accused Products”).
`56. By way of example, F&P markets both the Eson and Simplus Mask
`System as masks for sleep apnea, being one component for the continuous positive
`airway pressure (“CPAP”) therapy system.
`57. On information and belief, F&P offers for sale, sells, licenses, and/or
`distributes the Accused Products in the United States, including within this district,
`and/or imports the Accused Products into the United States.
`58. On information and belief, F&P was aware of ResMed’s products that
`practice the patents identified in this Complaint.
`59. F&P markets the structure, operation, and use of the Simplus System to
`the public.
`
`
`
`
`
`
`
`7
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`8
`
`

`
`
`
`60. By way of example, on its website, F&P markets the use of the Simplus
`System for Sleep Apnea:
`
`
`
`61. By way of example, on its website, F&P markets that the Simplus
`System includes three components, the RollFit Seal, the ErgoForm Headgear, and
`Easy Frame:
`
`
`62. By way of example, on its website, F&P markets the structure of the
`Simplus System including the RollFit Seal, the ErgoForm Headgear, and Easy
`Frame.
`
`
`
`
`
`
`
`8
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`9
`
`

`
`
`
`
`
`
`63. By way of example, on its website, F&P markets that the Simplus
`System includes a RollFit Seal:
`
`
`64. Below is a close up photo of the Simplus System RollFit Seal
`composed a two portions, a first portion of one material and a second portion of a
`second material that is more flexible than the first portion:
`
`
`
`
`
`
`
`
`9
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`10
`
`

`
`
`
`65. By way of example, on its website, F&P markets that the Simplus
`System includes a ErgoFoarm Headgear:
`
`
`66. By way of example, on its website, F&P markets that the Simplus
`System includes an Easy Frame:
`
`
`
`67. Below is a close up photo showing the Easy Frame, including an upper
`support member, two lower headgear clip attachments, an annular connection
`adapted to engage an elbow of an inlet conduit, and an opening located between the
`annular connection and the upper support member.
`
`10
`
`CASE NO._______
`
`
`
`
`
`
`
`
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`11
`
`

`
`
`
`68. By way of example, on its website, F&P markets the Mask Parts of the
`Simplus System:
`
`
`69. By way of example, on its website, F&P markets Fitting Your Mask for
`the Simplus System:
`
`11
`
`CASE NO._______
`
`
`
`
`
`
`
`
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`12
`
`

`
`
`
`
`
`70. By way of example, on its website, F&P markets Mask
`Assembly/Disassembly for the Simplus System:
`
`
`
`71. F&P markets the structure, operation, and use of the Eson System to
`the public. By way of example, F&P provides instruction to the public on the
`
`
`
`
`
`
`
`12
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`13
`
`

`
`
`
`structure, function, use, and purchasing on its website, including at least marketing
`materials, sales materials, purchasing information, videos, catalogues, specification
`sheets, user instructions, and guides. Further, by way of example, F&P provides
`instruction to the public on the structure, function, and use of the Eson System
`product in the product packaging; including at least user instructions.
`72. By way of example, on its website, F&P markets the use of the Eson
`System as a Nasal Mask for Sleep Apnea:
`
`
`
`73. By way of example, on its website, F&P markets that the Eson System
`includes three components, the RollFit Seal, the ErgoFit Headgear, and Easy Frame:
`
`
`
`
`
`
`
`13
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`14
`
`

`
`
`
`
`
`74. By way of example, on its website, F&P markets that the Eson System
`includes a RollFit Seal:
`
`
`75. By way of example, on its website, F&P markets that the Eson System
`includes a ErgoFit Headgear:
`
`
`
`
`
`
`
`
`
`14
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`15
`
`

`
`
`
`76. By way of example, on its website, F&P markets that the Eson System
`includes an Easy Frame:
`
`
`77. By way of example, on its website, F&P markets the Mask Parts of the
`Eson System:
`
`15
`
`CASE NO._______
`
`
`
`
`
`
`
`
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`16
`
`

`
`
`
`78. By way of example, on its website, F&P markets Fitting Your Mask for
`the Eson System:
`
`
`79. By way of example, on its website, F&P markets Mask
`Assemby/Disassembly for the Eson System:
`
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`
`
`
`
`80. On information and belief, F&P has imported the Eson 2 System as a
`Nasal Mask for Sleep Apnea:
`
`
`16
`
`CASE NO._______
`
`17
`
`

`
`
`
`81. By way of example, on its website, and in its promotional materials,
`including the materials accompanying the imported Eson 2 System, F&P markets
`that the Eson 2 System includes “Key features and benefits” including, the Intuitive
`Headgear, the RollFit Seal and the Easy Frame:
`
`
`
`
`
`
`
`
`
`
`82. By way of example, in the materials accompanying the imported Eson
`2 System F&P markets the Mask Parts of the Eson 2 System:
`
`
`
`
`
`
`
`17
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`18
`
`

`
`
`
`
`
`83. By way of example, in the materials accompanying the imported Eson
`2 System F&P markets Fitting Your Mask for the Eson 2 System:
`
`
`
`
`
`84. By way of example, in the materials accompanying the imported Eson
`2 System F&P markets Mask Assembly/Disassembly for the Eson
`2 System:
`
`
`
`
`
`
`
`18
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`19
`
`

`
`
`
`
`
`
`
`
`
`85. On information and belief, because F&P was aware of ResMed’s
`products, F&P was also aware of ResMed patents as a result of patent marking,
`including the marking on ResMed’s website. Moreover, F&P was aware of at least
`the ’404 patent and ’061 patents—and its infringement of the claims thereof—no
`later than on or about February 12, 2015, through written communications from
`ResMed to F&P and no later than on or on about March 4, 2015, through a meeting
`and presentation from ResMed to F&P notifying F&P of its infringement. F&P was
`also aware of at least the ’556 patent—and infringement of the claims thereof—no
`later than August and September 2015, through written communications and a
`meeting and presentation from ResMed to F&P notifying F&P of its infringement.
`86. On information and belief, F&P’s acts of infringement of the patents
`identified below have occurred with knowledge of ResMed’s rights in its patents or
`with willful blindness thereto.
`
`
`FIRST CLAIM FOR RELIEF
`F&P’S INFRINGEMENT OF U.S. PATENT NO. 8,944,061
`87. The allegations of Paragraphs 1-86 are incorporated herein by
`reference.
`
`
`
`
`
`
`
`19
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`20
`
`

`
`
`
`88. F&P has directly infringed the claims of the ’061 patent, literally and/or
`under the doctrine of equivalents, by using, offering to sell, and/or selling within the
`United States, and/or importing into the United States, the Accused Products,
`including but not limited to F&P's Simplus System product line.
`89. By way of example, the Accused Products, including at least the
`Simplus Mask System, specifically infringe at least claims 17, 18, 20, 21, 22, 23, 26,
`27, 28, 29, 30, 32, 33, 35, 36, 37, 38, 41, 42, 43, 44, 45, 46, 48, 49, 51, 52, 53, 54,
`55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76,
`77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, and 91 of the '061 patent.
`90. By way of example, the Accused Products specifically infringe at least
`independent claim 17 in the following way.
`91. The Accused Products include a mask assembly for treatment of sleep
`disorder breathing by delivering a flow of pressurized gas to a patient.
`92. By way of example, F&P markets the F&P Simplus System for the
`treatment of sleep apnea involving the delivery of a flow of pressurized gas to the
`wearer of the mask.
`93. The Accused Products include a first frame made of first material.
`94. By way of example, the F&P Simplus System includes a RollFit seal
`frame made of a first material.
`95. The Accused Products include a cushion connected to the first frame,
`the cushion being adapted to form a seal around a patient's nose and mouth and
`being made from a second material that is more flexible than the first material.
`96. By way of example, the F&P Simplus System RollFit Seal includes a
`first portion of one material and a second portion made of a second material forming
`a seal around a patient's nose and mouth and being made from a second material that
`is more flexible than the first material:
`
`
`
`
`
`
`
`20
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`21
`
`

`
`
`
`
`97. The Accused Products include a second frame adapted to constrain the
`first frame, the second frame comprising an upper support member that supports a
`forehead support, two lower headgear clip attachments engaged with clips provided
`to straps of a headgear assembly, an annular connection adapted to engage an elbow
`of an inlet conduit and an opening located between the annular connection and the
`upper support member, the opening providing access to the first frame.
`98. By way of example, the Easy Frame of the Simplus System is adapted
`to constrain the RollFit Seal.
`99. By way of example, the Easy Frame of the Simplus System includes an
`upper support member that supports a forehead support.
`
`
`100. By way of example, the Easy Frame of the Simplus System includes
`two lower headgear clip attachments engaged with clips provided to straps of a
`headgear assembly.
`
`
`
`
`
`
`
`21
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`22
`
`

`
`
`
`
`
`101. By way of example, the Easy Frame of the Simplus System includes an
`annular connection that adapted to engage an elbow—a ball and socket elbow—of
`an inlet conduit.
`
`
`
`102. By way of example, the Easy Frame of the Simplus System includes
`and an opening located between the annular connection and the upper support
`member, the opening providing access to the first frame.
`
`
`
`
`
`
`
`
`22
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`23
`
`

`
`
`
`
`103. ResMed is well-known in the industry for making and selling SDB
`products and ResMed is well-known in the industry to be an innovator.
`104. ResMed also gives notice to the public that its products are patented by
`appropriately marking those products with its applicable patent numbers as
`permitted by 35 U.S.C. §287(a).
`105. Therefore, on information and belief, F&P either must have known
`about the ’061 patent or must have been willfully blind to it at the time they engaged
`in their infringing activities and, in any event, was aware of the ’061 patent at least
`as early as the service date of this complaint.
`106. F&P was aware of the ’061 patent, at least in part through written
`communications from ResMed on or about February 12, 2015 and a meeting
`between ResMed and F&P on or about March 4, 2015 notifying F&P of its
`infringement of this patent.
`107. F&P also induces infringement of the ’061 patent. F&P encourages
`and intends the use, importation, and sale of the Accused Products within the United
`States. For example, at least on its website, F&P advertises the Accused Products
`for use within the United States and instructs patients to use the Accused Products.
`
`
`
`
`
`
`
`23
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`24
`
`

`
`
`
`108. On information and belief, F&P lacks reasonable defenses for their
`infringing activities and therefore knows the use, importation, and sale of the
`Accused Products within the United States infringes the ’061 patent.
`109. As a result of F&P’s infringement of the ’061 patent, ResMed has
`suffered and will continue to suffer damage.
`110. ResMed is entitled to recover from F&P the damages adequate to
`compensate for such infringement, which have yet to be determined.
`111. F&P’s acts of infringement have caused and will continue to cause
`irreparable harm to ResMed unless and until enjoined by this Court.
`
`
`SECOND CLAIM FOR RELIEF
`F&P’S INFRINGEMENT OF U.S. PATENT NO. 8,950,404
`112. The allegations of Paragraphs 1-111 are incorporated herein by
`reference.
`113. F&P has directly infringed the claims of the ’404 patent, literally and/or
`under the doctrine of equivalents, by using, offering to sell, and/or selling within the
`United States, and/or importing into the United States, the Accused Products,
`including but not limited to F&P’s Simplus System product line.
`114. By way of example, the Accused Products, including at least the
`Simplus Mask System, specifically infringe at least claims 1, 5, 6, 7, 8, 9, 15, 16, 17,
`27, and 28 of the ’404 patent. By way of example, the Accused Products, including
`at least the Eson 2 Mask System, specifically infringe at least claims 1, 5, 6, 7, 15,
`16, 17, 27, and 28 of the '404 patent.
`115. By way of example, the Accused Products specifically infringe at least
`claim 1 of the ’404 patent in the following way.
`116. The Accused Products include a headgear system for holding a
`respiratory mask in a position on a face of a patient to enhance a mask seal with the
`
`
`
`
`
`
`
`24
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`25
`
`

`
`
`
`patient's face, the headgear system including a plurality of straps providing a four-
`point arrangement for attachment with the respiratory mask.
`117. By way of example, the Simplus System includes an ErgoForm
`Headgear for holding a respiratory mask, the Simplus System RollFit Seal and Easy
`Frame, in a position on a face of a patient to enhance a mask seal with the patient's
`face, the ErgoForm Headgear including a plurality of straps providing a four-point
`
`arrangement for attachment with the Easy Frame.
`118. The Accused Products include at least one upper strap configured to
`extend above the patient’s ears in use.
`119. By way of example, the Simplus System ErgoForm Headgear includes
`at least one upper strap configured to extend above the patient’s ears in use.
`
`
`
`
`
`
`
`25
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`26
`
`

`
`
`
`120. The Accused Products include at least one lower strap configured to
`extend below the patient's ears in use.
`121. By way of example, the Simplus System ErgoForm Headgear includes
`at least lower strap configured to extend below the patient’s ears in use.
`
`122. The Accused Products include a rear portion.
`123. By way of example, the Simplus System ErgoForm Headgear includes
`a rear portion that contact the rear of the patient’s head.
`
`
`
`
`
`
`
`26
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`27
`
`

`
`
`
`
`124. The Accused Products include a headgear system wherein at least one
`strap of said plurality of straps is constructed from a laminate having at least a first
`fabric layer and a second fabric layer, said first fabric layer being constructed and
`arranged to be located on a patient-contacting side in use, and said second fabric
`layer being constructed and arranged to be located on a non patient-contacting side
`in use and further wherein said first fabric layer and said second fabric layer are
`joined at a joint configured to be positioned away from the patient's face when in
`use and wherein said at least one strap of said plurality of straps has a first rounded
`lateral edge when viewed in cross-section.
`125. By way of example, the Simplus System ErgoForm Headgear includes
`a headgear system wherein at least one strap of said plurality of straps is constructed
`from a laminate having at least a first fabric layer and a second fabric layer, said
`first fabric layer being constructed and arranged to be located on a patient-
`contacting side in use, and said second fabric layer being constructed and arranged
`to be located on a non patient-contacting side in use and further wherein said first
`fabric layer and said second fabric layer are joined at a joint configured to be
`positioned away from the patient's face when in use and wherein said at least one
`strap of said plurality of straps has a first rounded lateral edge when viewed in
`cross-section.
`
`
`
`
`
`
`
`27
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`28
`
`

`
`
`
`126. By way of example, below is a cross sectional view of the lower strap
`of Simplus System ErgoForm Headgear, which includes a laminate with a rounded
`edge having at least a first fabric layer and a second fabric layer joined at a joint
`configured to be positioned away from the patient's face.
`
`
`
`127. The Accused Products include a headgear system wherein the joint is
`positioned at approximately a center or middle of the first rounded lateral edge when
`viewed in cross section.
`128. By way of example, below is a cross sectional view of the lower strap
`of Simplus System ErgoForm Headgear, which includes a joint positioned at
`approximately a center or middle of the first rounded lateral edge when viewed in
`cross section.
`
`
`
`
`
`
`
`28
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`29
`
`

`
`
`
`
`
`129. ResMed is well-known in the industry for making and selling SDB
`products and ResMed is well-known in the industry to be an innovator.
`130. ResMed also gives notice to the public that its products are patented by
`appropriately marking those products with its applicable patent numbers as
`permitted by 35 U.S.C. §287(a).
`131. Therefore, on information and belief, F&P either must have known
`about the ’404 patent or must have been willfully blind to it at the time they engaged
`in their infringing activities and, in any event, was aware of the ’404 patent at least
`as early as the service date of this complaint.
`132. F&P was aware of the ’404 patent, at least in part through written
`communications from ResMed on or about February 12, 2015 and a meeting
`between ResMed and F&P on or about March 4, 2015 notifying F&P of its
`infringement of this patent.
`133. F&P also induces infringement of the ’404 patent. F&P encourages
`and intends the use, importation, and sale of the Accused Products within the United
`States. For example, at least on its website, F&P advertises the Accused Products
`for use within the United States and instructs patients to use the Accused Products.
`
`
`
`
`
`
`
`29
`
`CASE NO._______
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`30
`
`

`
`
`
`134. On information and belief, F&P lacks reasonable defenses fo

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket